Highlights
- Bio-Techne's pending Merck KGaA Merger is expected to close by late 2026 or early 2027, subject to customary closing conditions.
- Fiscal first quarter 2027 net sales were $299,712 thousand, compared with $286,555 thousand, and net Earnings were $28,293 thousand.
- Operating income was $36,603 thousand, compared with $47,658 thousand, and Diluted Earnings per Share were $0.18, compared with $0.24.
- Cash and cash equivalents were $350.0 million at September 30, 2026, with $800.0 million available on the line of credit.
Bio-Techne Corporation (NASDAQ:TECH) shares were trading at USD 72.77 on November 17, 2026, down 0.03%, with a relative Volume at time of 1.65. The biotechnology reagents, instruments and services company entered a merger agreement with Merck KGaA in June 2026, saw its shareholders vote to approve it on September 23, 2026, and filed its fiscal first quarter 2027 Form 10-Q on November 6, 2026.
Bio-Techne is a Minnesota corporation headquartered in Minneapolis, Minnesota. It develops, manufactures and sells biotechnology reagents, instruments and services for the research and clinical diagnostic markets worldwide. The Protein Sciences segment makes purified proteins and reagent solutions, including cytokines and growth factors, antibodies and immunoassays. The Diagnostics and Spatial Biology segment makes diagnostic products, including FDA-regulated controls and calibrators, clinical molecular diagnostic oncology assays and tissue-based in-situ hybridization assays. The fiscal year ends June 30. At November 2, 2026, 157,090,727 shares of common stock were outstanding.
Pending Merger With Merck KGaA
In June 2026, the company entered into an Agreement and Plan of Merger with Merck KGaA, Darmstadt, Germany, and EMD Holdings NewCo, Inc., a wholly-owned Subsidiary of Merck KGaA. Under the agreement, the subsidiary will merge with and into Bio-Techne, which will survive as a wholly-owned subsidiary of Merck KGaA. Shareholders voted to approve the Merger Agreement on September 23, 2026. The company said the merger is expected to close by late 2026 or early 2027, subject to satisfaction of additional customary closing conditions.
Fiscal First Quarter 2027 Results
For the quarter ended September 30, 2026, net sales were $299,712 thousand, compared with $286,555 thousand a year earlier. The company said net sales increased 5% and organic revenue, a non-GAAP measure, increased 7%. Gross Margin was $196,623 thousand, or 65.6% of net sales, the same percentage as a year earlier.
Selling, general and administrative expenses were $133,679 thousand, compared with $116,213 thousand, and Research and Development expenses were $26,341 thousand, compared with $24,241 thousand. Operating Income was $36,603 thousand, compared with $47,658 thousand. Net earnings were $28,293 thousand, compared with $38,185 thousand, and diluted earnings per share were $0.18, compared with $0.24.
Non-GAAP adjusted net earnings were $70,105 thousand, compared with $66,039 thousand, and adjusted diluted earnings per share were $0.44, compared with $0.42. The adjustments included Acquisition related expenses and other of $17,906 thousand, compared with $3,508 thousand.
Protein Sciences net sales were $219,691 thousand, compared with $202,188 thousand, with an Operating Margin of 37.9%, compared with 38.4%. Diagnostics and Spatial Biology net sales were $80,164 thousand, compared with $79,458 thousand, with an operating margin of 7.4%, compared with 11.2%.
Balance Sheet, Cash Flow and Capital
Cash and cash equivalents were $350.0 million at September 30, 2026, compared with $264.7 million at June 30, 2026. Short-Term Debt obligations were $200,000 thousand at September 30, 2026, and long-term debt obligations were $200,000 thousand at June 30, 2026. The Credit agreement matures on August 31, 2027, and $800.0 million was available on the line of credit.
Operating activities generated $73.1 million of cash in the quarter, compared with $27.6 million. The company paid cash dividends of $12.6 million, compared with $12.4 million.
Outlook and Plans
The company expects Capital expenditures for the remainder of fiscal 2027 of approximately $28 million. Excluding discrete items, it expects the consolidated income tax rate for the remainder of fiscal 2027 to range from 23% to 27%.
The company must acquire the remaining 80.1% of Wilson Wolf on December 31, 2027, under a forward contract, and the contract would be accelerated if Wilson Wolf meets certain financial milestones. The second option payment of approximately $1 billion plus potential contingent consideration is forecasted to occur between fiscal 2027 and fiscal 2028.






Please wait processing your request...